Grant ID RP150386
Awarded On February 18, 2015
Title A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Jack Phan
Cancer Sites Head and Neck
Contracted Amount $662,386.81
Award Transfer Information

Previous Organization: The University of Texas Southwestern Medical Center

Expended at Previous Organization: $198,153.19

Lay Summary

Laryngeal cancer is the most common throat cancer in the U.S. Chemoradiation is standard-of-care for advanced disease. Seven weeks of daily treatments are needed for this. Treatment is costly and toxic. Over a quarter of patients suffer local recurrence within 5 years, and over half ultimately lose their voicebox. No significant advances have been made for this cancer in several decades. Patients deserve more potent therapy which spares throat function. We hypothesize that stereotactic body radiation (SBRT) will achieve this goal. We will lead a phase I dose-escalation trial of SBRT given in five treatments over 11⁄2 weeks for advanced laryngeal disease at UT Southwestern and UT M.D. Anders...

Read More